GlassScriptPhysician profile
Paul D Gittelman
NPI 1689761686
$6,020.30
in general payments reported to CMS, 2019-2025
29 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $519 · 2021: $365 · 2022: $891 · 2023: $1,519 · 2024: $828 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,122.78 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $892.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $855.86 | 2021-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $703.34 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $456.57 | 2019-2025 | Fasenra |
| Csl Behring | $252.62 | 2019-2025 | Hizentra |
| Neurent Medical Limited | $197.08 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Regeneron Healthcare Solutions, INC. | $172.77 | 2019-2025 | Dupixent |
| Acclarent, INC | $159.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.82 | 2020-2023 | Hyqvia, Cuvitru |
| Kaleo, INC. | $128.47 | 2019-2024 | Auvi-Q |
| Shire North American Group INC | $117.65 | 2019 | |
| Genentech USA, INC. | $115.53 | 2023-2025 | Xolair |
| Hikma Pharmaceuticals USA | $86.32 | 2022-2024 | Ryaltris |
| Alk-Abello, INC | $85.80 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $84.46 | 2023-2025 | Inspire |
| Stryker Corporation | $83.71 | 2019-2024 | Scopis Ent |
| Intersect Ent, INC. | $67.17 | 2019-2022 | |
| Medtronic, INC. | $52.15 | 2023-2025 | Sinuva, Stealthstation S8 Platform |
| Lilly USA, LLC | $45.69 | 2025 | Zepbound |
| Blueprint Medicines Corporation | $29.76 | 2023 | Ayvakit |
| Arbor Pharmaceuticals, INC. | $28.06 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.77 | 2025 | Xhance |
| Pharming Healthcare, INC. | $20.75 | 2020 | |
| Grifols USA, LLC | $20.74 | 2023 | Xembify |
| Amgen INC. | $20.04 | 2021 | |
| Merck Sharp & Dohme LLC | $19.27 | 2023 | |
| Pfizer INC. | $18.57 | 2023 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gittelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.